Get started
Author

Aurelio Marsiglio

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2007 · Patrizia Carpinelli, Roberta Ceruti, et al. · Molecular Cancer Therapeutics · 248
1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a Potent Aurora Kinase Inhibitor with a Favorable Antitumor Kinase Inhibition Profile
2006 · Daniele Fancelli, Jürgen Moll, et al. · Journal of Medicinal Chemistry · 190
3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 1. Lead Finding
2004 · Paolo Pevarello, Maria Gabriella Brasca, et al. · Journal of Medicinal Chemistry · 167
Potent and Selective Aurora Inhibitors Identified by the Expansion of a Novel Scaffold for Protein Kinase Inhibition
2005 · Daniele Fancelli, Daniela Berta, et al. · Journal of Medicinal Chemistry · 147
3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 2. Lead Optimization
2005 · Paolo Pevarello, Maria Gabriella Brasca, et al. · Journal of Medicinal Chemistry · 110
Synthesis and Biological Evaluation of RGD Peptidomimetic–Paclitaxel Conjugates Bearing Lysosomally Cleavable Linkers
2015 · Alberto Dal Corso, Michele Caruso, et al. · Chemistry - A European Journal · 53
Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases
2013 · Francesco Casuscelli, Elena Ardini, et al. · Bioorganic & Medicinal Chemistry · 38
Thieno[3,2-c]pyrazoles: A novel class of Aurora inhibitors with favorable antitumor activity
2010 · Simona Bindi, Daniele Fancelli, et al. · Bioorganic & Medicinal Chemistry · 30
Benzodipyrazoles: a new class of potent CDK2 inhibitors
2005 · Roberto D’Alessio, Alberto Bargiotti, et al. · Bioorganic & Medicinal Chemistry Letters · 30
Antitumor activity of FCE 26644 a new growth-factor complexing molecule
1995 · Francesco Sola, Mariella Farao, et al. · Cancer Chemotherapy and Pharmacology · 27
Tumor Targeting with an isoDGR–Drug Conjugate
2017 · Simone Zanella, Simona Angerani, et al. · Chemistry - A European Journal · 19
PDF
Targeting Integrin α V β 3 with Theranostic RGD‐Camptothecin Conjugates Bearing a Disulfide Linker: Biological Evaluation Reveals a Complex Scenario
2017 · Arianna Pina, A. Dal Corso, et al. · ChemistrySelect · 18
PDF
In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time
2003 · Massimiliano Germani, Paolo Magni, et al. · Cancer Chemotherapy and Pharmacology · 9
Abstract 734: Thienoindoles: New highly promising agents for antibody-drug conjugates generation
2018 · Michele Caruso, Fabio Gasparri, et al. · Cancer Research · 4
Abstract 822: Thienoindoles, a novel class of DNA minor groove alkylating agents highly suited for the generation of novel antibody drug conjugates (ADCs)
2014 · Barbara Valsasina, Fabio Gasparri, et al. · Cancer Research · 2
Nemorubicin: A doxorubicin-like structure with a novel mechanism of action different from anthracyclines
2006 · Cristina Geroni, Maria Antonietta Sabatino, et al. · Cancer Research · 2
3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 2. Lead Optimization.
2005 · Paolo Pevarello, Maria Gabriella Brasca, et al. · Journal of Medicinal Chemistry · 1
Data from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023 · Patrizia Carpinelli, Roberta Ceruti, et al.
Data from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023 · Patrizia Carpinelli, Roberta Ceruti, et al.
Supplementary Table S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023 · Patrizia Carpinelli, Roberta Ceruti, et al.
PDF
Supplementary Fig. S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023 · Patrizia Carpinelli, Roberta Ceruti, et al.
PDF
Abstract A149: NMS-P945, a highly active payload for antibody drug conjugates generation
2015 · Fabio Gasparri, Michele Caruso, et al. · Molecular Cancer Therapeutics
Abstract B230: NMS-P948, a potent dual FLT3/KIT inhibitor, also active on secondary resistance mutations.
2011 · Marina Ciomei, Ivan Fraietta, et al. · Molecular Cancer Therapeutics
Nemorubicin synergizes with agents currently used for the treatment of hepatocellular carcinoma (HCC)
2007 · Cristina Geroni, Dario Ballinari, et al. · Molecular Cancer Therapeutics
Works count: 24
Citation count: 1,095
H-index: 12
I10-index: 12
Year
Topic
Type